Imunon Inc. (NASDAQ: IMNN) plans to host an R&D day on September 23, 2026, to discuss progress on its DNA-mediated IL-12 immunotherapy IMNN-001 for advanced ovarian cancer.
The event, scheduled to begin at 1:00 PM ET at the Sofitel New York, will feature presentations on the company’s lead clinical program and include a live virtual broadcast for investors, analysts and the media. Imunon, based in Lawrenceville, N.J., will provide updates on its OVATION 3 Phase 3 trial evaluating IMNN-001 in women newly diagnosed with advanced ovarian cancer.
The R&D day will also cover results from the OVATION 2 Phase 2 study, which assessed weekly intraperitoneal doses of IMNN-001 combined with chemotherapy versus standard of care alone in 112 patients. Imunon additionally plans to discuss its prophylactic vaccine IMNN-101, which has completed dosing in a first-in-human study.
The company will host the event in partnership with Break Through Cancer, with research led by investigators at The University of Texas MD Anderson Cancer Center.
